Latest news and articles about coronavirus from NEX English
Recent studies have revealed promising signals that could help in the fight against the novel coronavirus. These discoveries open new avenues in medical research at a critical time as the world continues to grapple with the pandemic's effects.
The Indonesian Ministry of Health has announced close monitoring of a new COVID-19 variant known as 'Cicada'. Although it has not yet been detected in Indonesia, the ministry urges citizens to remain vigilant.
The Israeli Ministry of Health has reported a significant rise in coronavirus cases, with active cases exceeding <strong>5000</strong>. This surge raises fears of a new outbreak as the government intensifies vaccination campaigns.
A recent study has found that COVID-19 may increase the risk of heart disease even among healthy individuals. These findings raise concerns about the long-term health effects of the virus.
Local sources reported that a café owner in Desouk closed the café's doors on customers after the designated closing time, sparking widespread debate over adherence to government regulations.
Commercial tower owners in Egypt express growing concerns about the government's decision to mandate early shop closures. They fear this move could negatively impact their businesses and increase existing financial pressures.
The Director of Emergency at the World Health Organization confirmed that the drug Dexamethasone represents a significant breakthrough in combating COVID-19. This medication, typically used for treating inflammation, has proven effective in reducing mortality among patients requiring respiratory support.
The Russian Federal Service for Surveillance in Consumer Rights Protection has reported no cases of the new coronavirus variant in the country, reflecting a stable health situation in Russia amidst global concerns over new variants.
The Thai Ministry of Public Health announced that the COVID-19 variant known as 'Cicada' is expected to arrive in the country. However, it does not pose a serious threat and no additional vaccinations are required.
Pfizer has announced that its experimental vaccine for Lyme disease demonstrates an efficacy of up to <strong>73%</strong>. However, concerns have been raised regarding the low number of cases in the trial, casting doubt on the vaccine's broader effectiveness.